52 studies found for:    "Genital Diseases, Female" | Japan
Show Display Options
Rank Status Study
1 Unknown  Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)
Condition: Uterine Cervical Neoplasms
Interventions: Drug: chemotherapy: Paclitaxel/Cisplatin;   Drug: chemotherapy: Paclitaxel/Carboplatin
2 Completed
Has Results
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Condition: Pelvic Inflammatory Disease
Intervention: Drug: Azithromycin
3 Completed Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
4 Completed Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
5 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
6 Completed A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
7 Active, not recruiting A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
Condition: Endometriosis
Interventions: Drug: ASP1707;   Drug: Placebo;   Drug: Leuprorelin acetate
8 Active, not recruiting Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
Condition: Endometriosis
Interventions: Drug: EE20/DRSP(BAY86-5300);   Drug: Placebo;   Drug: Dienogest
9 Recruiting Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: temsirolimus;   Drug: docetaxel;   Other: laboratory biomarker analysis
10 Recruiting Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Atypical Glandular Cell of Undetermined Significance;   Cervical Cancer;   Cervical Intraepithelial Neoplasia Grade 2;   Cervical Intraepithelial Neoplasia Grade 3;   Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
11 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
12 Active, not recruiting TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
13 Active, not recruiting
Has Results
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Neoplasms, Ovarian
Interventions: Drug: Pazopanib;   Drug: Placebo
14 Recruiting Bay98-7196, Dose Finding / POC Study
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: Levonorgestrel;   Drug: Anastrozole + Levonorgestrel (BAY 98-7196);   Drug: Lupron / Leuprolide acetate
15 Unknown  Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
16 Active, not recruiting TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: Paclitaxel;   Drug: AMG 386 Placebo;   Drug: Carboplatin
17 Active, not recruiting
Has Results
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Other: hydrocortisone/placebo;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
18 Recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
19 Completed The Study Of Fluconazole For Vulvovaginal Candidiasis
Condition: Vulvovaginal Candidiasis
Intervention: Drug: Fluconazole
20 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years